Songmin Ying | Immunology | Best Researcher Award

Published on 18/03/202529/03/2025 by Zoology Honour

Prof. Dr. Songmin Ying | Immunology | Best Researcher Award

MD, PhD at Zhejiang University, China

Songmin Ying is a Qiushi Distinguished Professor and Doctoral Supervisor at Zhejiang University School of Medicine. He serves as the Executive Dean and Director of the Zhejiang-Denmark Joint Laboratory for Regenerative and Aging Medicine. His research focuses on chronic airway diseases, aging medicine, and pharmacology. Dr. Ying has held various prestigious academic and research positions, including at the University of Oxford and the Technical University of Munich. With an extensive publication record in high-impact journals, he has significantly contributed to immunology, oncology, and respiratory medicine. His pioneering research has garnered numerous accolades, cementing his reputation as a leader in biomedical sciences.

Professional Profiles

Google Scholar

Education

Dr. Ying’s academic journey began at Shantou University School of Medicine, where he earned his Bachelor’s degree in Clinical Medicine (2003-2007). He then pursued a Master’s in Molecular Genetic Medicine at the University of Sheffield (2007-2010), followed by a Doctorate in Biochemistry at the Technical University of Munich (2010-2013). His postdoctoral training took place at the University of Oxford in the Department of Oncology and the Weatherall Institute of Molecular Medicine. This diverse and prestigious academic background has equipped him with expertise in molecular medicine, respiratory diseases, and translational pharmacology.

Work Experience

Dr. Ying’s career is marked by leadership roles in medical research and academia. He has been a Research Fellow and Professor at the Institute of Respiratory Diseases, Zhejiang University, since 2013. In 2023, he was appointed Executive Dean of Zhejiang University School of Medicine, where he oversees groundbreaking biomedical research. His role as Director of the Zhejiang-Denmark Joint Laboratory for Regenerative and Aging Medicine reflects his global research collaborations. His extensive international experience includes significant contributions at the University of Oxford and other renowned institutions.

Awards and Honors 🏆

Dr. Ying has received numerous awards for his contributions to medical research, particularly in immunology and respiratory diseases. He has been recognized with the Qiushi Distinguished Professorship, Zhejiang University’s highest honor. His research has also earned prestigious grants and fellowships, reflecting his impact on aging medicine and airway disease research. He has been invited as a keynote speaker at leading medical conferences worldwide, further solidifying his influence in the scientific community.

Skills💡

Dr. Ying possesses expertise in molecular biology, immunology, pharmacology, and respiratory medicine. His skills include high-throughput sequencing, CRISPR gene editing, and advanced imaging techniques. He is also proficient in bioinformatics analysis and translational medicine strategies. As an academic leader, he has extensive experience in mentoring PhD students and leading multidisciplinary research teams. His collaboration with international institutions enhances his ability to drive innovation in medical sciences.

Research Focus 🔬

Dr. Ying’s research centers on chronic airway diseases, aging medicine, and pharmacology. His work explores the molecular mechanisms of immune responses in respiratory disorders, with an emphasis on eosinophilic inflammation and metabolic adaptation in allergic diseases. He investigates aging-related pathologies and regenerative medicine, aiming to develop targeted therapies for age-associated respiratory diseases. His interdisciplinary approach integrates genomics, bioinformatics, and experimental medicine, positioning his work at the forefront of translational research.

Conclusion

Publications Top Notes

Replication stress induces sister-chromatid bridging at fragile site loci in mitosis

Citations: 674

Year: 2009

Replication stress activates DNA repair synthesis in mitosis

Citations: 571

Year: 2015

Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1

Citations: 394

Year: 2012

MUS81 promotes common fragile site expression

Citations: 281

Year: 2013

Chlamydia Inhibit Host Cell Apoptosis by Degradation of Proapoptotic BH3-only Proteins

Citations: 253

Year: 2004

Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments

Citations: 209

Year: 2018

Activation of MTOR in pulmonary epithelium promotes LPS-induced acute lung injury

Citations: 201

Year: 2016

Autophagy is essential for ultrafine particle-induced inflammation and mucus hyperproduction in airway epithelium

Citations: 178

Year: 2016

Genetic alterations in esophageal tissues from squamous dysplasia to carcinoma

Citations: 170

Year: 2017

Recruitment of BAD by the Chlamydia trachomatis vacuole correlates with host-cell survival

Citations: 158

Year: 2006

Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis

Citations: 140

Year: 2015

Pathological roles of neutrophil‐mediated inflammation in asthma and its potential for therapy as a target

Citations: 123

Year: 2017

Inactivation of MTOR promotes autophagy-mediated epithelial injury in particulate matter-induced airway inflammation

Citations: 114

Year: 2020

LncRNA H19 promotes the proliferation of pulmonary artery smooth muscle cells through AT1R via sponging let-7b in monocrotaline-induced pulmonary arterial hypertension

Citations: 106

Year: 2018

MTOR suppresses cigarette smoke–induced epithelial cell death and airway inflammation in chronic obstructive pulmonary disease

Citations: 102

Year: 2018

DNA-PKcs and PARP1 bind to unresected stalled DNA replication forks where they recruit XRCC1 to mediate repair

Citations: 96

Year: 2016

Broad Degradation of Proapoptotic Proteins with the Conserved Bcl-2 Homology Domain 3 during Infection with Chlamydia trachomatis

Citations: 94

Year: 2005

ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation

Citations: 88

Year: 2021

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis

Citations: 85

Year: 2017

Autophagy plays an essential role in cigarette smoke-induced expression of MUC5AC in airway epithelium

Citations: 82

Year: 2016

Zhong-Yi Dong | Oncology | Best Researcher Award

Published on 17/03/202529/03/2025 by Zoology Honour

Pr. Zhong-Yi Dong | Oncology | Best Researcher Award

Teacher at Universidade Federal do Oeste do Pará, China

Dr. Dong Zhongyi, born in August 1985, is an esteemed oncologist specializing in tumor radiotherapy. With over a decade of experience, he serves as Associate Chief Physician in the Department of Radiotherapy at Southern Hospital, Southern Medical University. He leads the lung cancer subspecialty group and mentors postgraduate students. Dr. Dong has received numerous accolades, including recognition in the “World’s Top 2% Scientists” (2024) and the “Guangdong Special Support Plan for Young Top Talents in Health.” His research contributions include over 20 high-impact publications and multiple national patents. He has been invited to present at international and domestic conferences and has secured major research grants. Dr. Dong actively participates in academic leadership, holding key positions in multiple professional medical committees in Guangdong, China. His work significantly advances the field of oncology, particularly in radiotherapy and immunotherapy for lung cancer.

Professional Profiles

ORwID

Education

Dr. Dong Zhongyi pursued his medical education at prestigious institutions, building a strong foundation in oncology and clinical medicine. He earned his Bachelor of Clinical Medicine from the University of South China, School of Medicine (2004-2009). This early training equipped him with essential medical knowledge and clinical skills. Following his undergraduate studies, he specialized further by obtaining a Master’s degree in Oncology (2009-2012) from Southern Hospital, Southern Medical University. During this time, he developed expertise in cancer treatment and research, particularly in radiotherapy and targeted therapies. Dr.Dong then advanced his academic journey with a Ph.D. in Oncology (2014-2017) from the Lung Cancer Research Institute, Guangdong Provincial People’s Hospital, under the mentorship of Professor Yilong Wu. His doctoral research focused on the molecular mechanisms of immune resistance and tumor microenvironments, providing critical insights into cancer progression and treatment strategies. This work laid the foundation for his impactful contributions to clinical oncology and translational medicine.

Work Experience

Dr. Dong Zhongyi has built a distinguished career in oncology, marked by extensive clinical practice, research, and teaching in tumor radiotherapy. He began his professional journey as a Resident Physician (2012-2014) at Xiangtan Central Hospital, Hunan Province, where he gained hands-on experience in patient care and medical oncology. This period helped him develop a strong clinical foundation in cancer treatment. Following this, he advanced to the role of Attending Physician (2017-2022) at Southern Hospital, Southern Medical University, where he further honed his expertise in lung cancer treatment and radiotherapy. His dedication to integrating research with clinical practice significantly improved patient outcomes. Currently, Dr. Dong serves as an Associate Chief Physician (2022-Present) at Southern Hospital, Southern Medical University, where he continues to lead advancements in oncology. In addition to his clinical role, he is deeply involved in medical education, serving as a Master’s Supervisor (2021-Present) and Doctoral Supervisor (2024-Present). Throughout his career, Dr. Dong has remained at the forefront of lung cancer research, pioneering innovative treatment strategies and leading multiple research projects. His commitment to mentoring young medical professionals has played a crucial role in shaping the next generation of oncologists

Awards and Honors 🏆

Dr. Dong Zhongyi has received numerous prestigious awards in recognition of his exceptional contributions to lung cancer research and oncology. He was honored with the “Guangdong Special Support Plan for Young Top Talents in Health,” reflecting his leadership in medical research. In 2024, he was listed among the “World’s Top 2% Scientists,” a testament to his global impact in oncology. His achievements in lung cancer research were further acknowledged when he ranked 41st among China’s Top 100 Schors in Lung Cancer (2022). Additionally, he received the IASLC Developing Nation Award twice, in 2016 and 2020, highlighting his contributions to international lung cancer research. In 2020, Dr. Dong was awarded the First Prize of the Guangdong Natural Science Award, recognizing his groundbreaking work in tumor radiotherapy and cancer treatment. His dedication to advancing oncology has also been supported by prestigious talent programs, including the “National Outstanding Young Scientist Cultivation Plan (Class A)” and the “Excllent Young Scientist Cultivation Plan” by Southern Medical University. These accolades underscore Dr. Dong’s remarkable impact on the field, cementing his status as a leading researcher and clinician in lung cancer treatment and translational medicine.

Skills💡

Dr. Dong Zhongyi is a distinguished expert in oncology research and clinical application, seamlessly integrating cutting-edge research into patient care. His expertise in radiotherapy and immunotherapy has contributed to advanced cancer treatment strategies, improving therapeutic outcomes. With a strong foundation in molecular and translational medicine, he continuously innovates in tumor biology, enhancing precision oncology approaches. As a prolific researcher, Dr. Dong has authored over 20 high-impact scientific papers, demonstrating his excellence in scientific writing and publishing. His commitment to academic mentorship is evident in his role as a supervisor for postgraduate research, nurturing the next generation of oncology professionals. Additionally, his contributions to medical innovation and patents—holding multiple invention patents—underscore his role as a leader in oncology research and education. Through these skills, Dr. Dong continues to drive advancements in cancer treatment and medical science.

Research Focus 🔬

Dr. Dong Zhongyi’s research encompasses both clinical and translational oncology, with a strong focus on advancing lung cancer treatment. His work in radiotherapy and immunotherapy has led to significant advancements in treatment strategies, improving patient survival and quality of life. He has extensively investigated the molecular mechanisms of immune resistance, shedding light on how tumor microenvironments influence therapy effectiveness. Additionally, Dr. Dong has contributed to understanding and mitigating the adverse effects of immunotherapy, developing strategies to enhance patient safety and treatment efficacy. His groundbreaking research has influenced global oncology guidelines and has been cited in expert consensus documents, underscoring his role in shaping the future of cancer care. By refining precision medicine approaches, his work continues to drive innovation in oncology, ultimately improving patient outcomes worldwide.

Conclusion

Publications Top Notes

CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

Journal: Nature Communications

Year: 2023

PMID: 36871040